Compare VRT & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRT | BMY |
|---|---|---|
| Founded | N/A | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.1B | 113.5B |
| IPO Year | 2018 | N/A |
| Metric | VRT | BMY |
|---|---|---|
| Price | $301.08 | $55.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 15 |
| Target Price | ★ $269.44 | $61.73 |
| AVG Volume (30 Days) | 5.4M | ★ 10.0M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | 0.08% | ★ 4.38% |
| EPS Growth | ★ 166.41 | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.04 | N/A |
| Revenue Next Year | $23.82 | N/A |
| P/E Ratio | $315.08 | ★ $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $110.06 | $42.52 |
| 52 Week High | $379.94 | $62.89 |
| Indicator | VRT | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 44.55 |
| Support Level | $293.88 | $53.98 |
| Resistance Level | $345.18 | $57.43 |
| Average True Range (ATR) | 15.87 | 1.32 |
| MACD | -2.03 | 0.03 |
| Stochastic Oscillator | 40.44 | 39.97 |
Vertiv has roots tracing back to 1946 when its founder, Ralph Liebert, developed an air-cooling system for mainframe data rooms. As computers started making their way into commercial applications in 1965, Liebert developed one of the first computer room air conditioning, or CRAC, units, enabling the precise control of temperature and humidity. The firm has slowly expanded its data center portfolio through internal product development and the acquisition of thermal and power management products like condensers, busways, and switches. Vertiv has global operations today; its products can be found in data centers in most regions throughout the world.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.